Revenue Recognition (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Allowances on accounts receivable	$ 8,018	$ 7,259	$ 6,481	$ 3,830
Other assets	36,897	25,787
Deferred revenue	$ 41,969	36,592	35,740
Product
Disaggregation of Revenue [Line Items]
Approximate percentage of revenue collected within 9 months	90.00%
Billing collection period (in months)	9 months
Extended billing collection period (in months)	6 months
Tests delivered in prior periods that were fully collected
Disaggregation of Revenue [Line Items]
Increased (decreased) revenues	$ 194,400	151,200	5,300
(Increased) decreased net loss	$ 194,400	$ 151,200	$ 5,300
(Increased) decreased net loss per share	$ 1.42	$ 1.21	$ 0.05
BGI Genomics
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 16,800
BGI Genomics | Oncology assay interpretation services
Disaggregation of Revenue [Line Items]
Revenue recognized	500	$ 1,600
Revenue, remaining performance obligation	20,000
BGI Genomics | Royalty
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 500	$ 1,400